Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Regulation

Happy New Year, Generics: Early FY 2015 Data Show FDA Getting Handle On ANDAs

  • News

Executive Summary

Approvals increased and submissions decreased through first two months of fiscal year 2015 compared to same period in FY 2014.

You may also be interested in...



ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.

Sentinel Could Be Used For Pregnancy Safety Studies Under PDUFA VII

User fee program inflation adjustment also proposed to be changed to account for only PDUFA-related personnel.

Table

View full table

Topics

Tags:
BioPharmaceutical United States Regulation
UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By